PURE PHARMA
ActiveSummary
The computed 12-month bankruptcy probability of PURE PHARMA is 1.9% (moderate). The 2025 annual accounts show equity of €383,549 and a net result of -€256,645. Equity is growing by about 9.5% per year across the filed financial years. Its solvency ranks better than 28% of 1,021 sector peers (NACE 41, financial year 2025). The company has been active since 2014 and the Belgian Official Gazette contains no insolvency or warning signals.
Articles of association
- Who signsWho may bind the company towards others, for example by signing a contract.
- “Allen benoemd tot de jaarvergadering te houden in 2028 over het boekjaar eindigend op 31/12/2027. Onverminderd de bevoegdheid van het…”
Read from the deeds: 1 provision, deed of 29-08-2024